SCHEMBL3259307

SCHEMBL3259307

O=C(NC1(Cc2ccc(Cl)cc2)CC1)c1ccc(S(=O)(=O)Nc2nccs2)cc1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
SCN3A Q9NY46 7/20 0.55
SCN5A Q14524 1/20 0.53
SCN9A Q15858 1/20 0.53
PPIA P62937 1/20 0.53
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
MAPT P10636 2/20 0.51
ALDH1A1 P00352 1/20 0.51
HTT P42858 1/20 0.51
AVPR2 P30518 1/20 0.50
GPR27 Q9NS67 1/20 0.50
KDM4E B2RXH2 1/20 0.49
RXFP1 Q9HBX9 1/20 0.48
PTPN1 P18031 1/20 0.48
PTPN11 Q06124 1/20 0.48
PTPN22 Q9Y2R2 1/20 0.48
ALOX12 P18054 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3258616 0.89 SCN3A (0.56) LMNASMN1; SMN2SCN3ASCN5ASCN9A
SCHEMBL3168911 0.88 PTPN1 (0.63) SCN3AMEN1KMT2AALDH1A1KDM4E
SCHEMBL3258222 0.85 SCN3A (0.56) LMNASMN1; SMN2SCN3ASCN5ASCN9A
SCHEMBL14777740 0.83 SCN3A (0.56) SCN3APPIAMEN1KMT2AALDH1A1
SCHEMBL3158840 0.83 LMNA (0.63) LMNASMN1; SMN2SCN3ASCN5ASCN9A
SCHEMBL3164238 0.82 SCN3A (0.80) LMNASMN1; SMN2SCN3ASCN5ASCN9A
SCHEMBL3158690 0.81 SCN3A (0.54) LMNASCN3ASCN9AMEN1KMT2A
SCHEMBL3169764 0.80 SMN1; SMN2 (0.65) LMNASMN1; SMN2SCN3ASCN5ASCN9A
SCHEMBL3153389 0.79 ALDH1A1 (0.54) LMNASCN3ASCN9AMEN1KMT2A
SCHEMBL3259319 0.76 LMNA (0.53) LMNASMN1; SMN2SCN3ASCN5ASCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8741934-B2 Inhibitors of ion channels PFIZER LIMITED (GB) 2014-06-03 US disclosed
US-20130072471-A1 Inhibitors of Ion Channels MARRON BRIAN EDWARD (US) 2013-03-21 US disclosed
US-8357711-B2 Heterocyclic sulfonamides as inhibitors of ion channels PFIZER LIMITED (GB) 2013-01-22 US disclosed
EP-1995241-B1 Inhibitors of ion channels ICAGEN INC (US) 2010-03-17 EP disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed
EP-1995241-A1 Inhibitors of ion channels ICAgen, Incorporated (US) 2008-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072471-A1 Inhibitors of Ion Channels TRPV1, TRPV5, TRPA1 LMNA 3442/4885SMN1; SMN2 445/4885SCN3A 13/4885
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 LMNA 3442/4885SMN1; SMN2 445/4885SCN3A 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.